Cancer and deep vein thrombosis – editorial
Authors:
J. Malý
Authors‘ workplace:
II. interní klinika Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc
Published in:
Vnitř Lék 2010; 56(1): 11-13
Category:
Editorials
Overview
Cancer patients with thrombosis and haemorrhagy are a particular problem. They have an increased risk of deep vein thrombosis and pulmonary embolism, and they’re more prone to bleeding from anticoagulant therapy. So it really is a dilemma. Clinical research has shown that prevention and initial therapy can consist of subcutaneous low-molecular-weight heparin for an initial period, followed by long‑term anticoagulant therapy.
Key words:
cancer – deep vein thrombosis – long‑term anticoagulant therapy
Sources
1. Trousseau A. Phlegmasia alba dolens. In: J. B. Balliére et al. Anonymous Médical de Hotel‑Dieu de Paris. Paris 1865: 652–695.
2. Bouillaud SD. Obliteration des veines et de son influence sur la formation des hydropisies partielles: consideration sur la hydropisies passive et general. Arch Gen Med 1823; 1: 188–204.
3. Büller H, TenCate JW. Primary venous thromboembolism and cancer screening. Editorial. N Engl J Med 1998; 338: 1221–1222.
4. Malý J, Dulíček P, Blažek M et al. Trombofilní stavy – laboratorní a klinická diagnostika. Interv Akut Kardiol 2007; 6 (Suppl B): B11–B16.
5. Prandoni P, Samama MM. Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients. Brit J Haematol 2008; 141: 587–597.
6. Kakkar VV. Prevention and management of venous thrombosis. Br Med Bull 1994; 50: 871–903.
7. Levine M. Treatment of Thrombotic Disorders in Cancer Patients. Haemostasis 1997; 27 (Suppl 1): 38–43.
8. Prins MH. Cancer and thrombosis. Proc. Symposium Deep vein thrombosis. State of the art – Geneve 1999.
9. Widimský J, Malý J, Eliáš P et al. Doporučení diagnostiky, léčby a prevence plicní embolie, verze 2007. Vnitř Lék 2008; 54 (Suppl 1): S25–S72.
10. Malý J, Dulíček P, Penka M et al. Prevence žilní tromboembolické nemoci ve vnitřním lékařství a v neurologii. Vnitř Lék 2006; 52 (Suppl 1): 63–67.
11. Prandoni P et al. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128–1233.
12. Le Gal G, Righini M, Roy PM et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med 2006; 144: 165–171.
13. Kucher N, Koo S, Quirit R et al. Electronic alert to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005; 352: 969–972.
14. Hirsh J, Guyatt G, Albers GW et al. American College of Chest Physicians. Evidence‑based clinical practice guidelines (8th ed). Executive summary. Chest 2008; 133 (Suppl): 71S–109S.
15. Lee AY, Levine MN, Baker RI et al. Randomized Comparison of Low‑Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low‑molecular‑weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146–153.
16. Kakkar AK, Levine MN, Kadziola Z et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944–1948.
17. Klerk CP, Smorenburg SM, Otten HM et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 2130–2135.
18. Niers TM, Di Nisio M, Klerk CP et al. Prevention of catheter‑related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo‑controlled study. J Thromb Haemost 2007; 5: 1878–1882.
19. Kakkar AK. Current use of venous thromboembolism prophylaxis in cancer patients. Clin Adv Hematol Oncol 2009; 7: 231–233.
20. Malý J. Délka antikoagulační léčby a riziko recidiv u TEN – editorial. Vnitř Lék 2007; 53: 629–631.
21. Meyer G, Marjanovic Z, Valcke J et al. Comparison of low‑molecular‑weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162: 1729–1735.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
![Issue 1](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/dc9a1f365a72d94e3fedc03dad9897d1.jpeg)
2010 Issue 1
Most read in this issue
- Patients older than 80 years with de novo acute myeloid leukemias without erythroblastic and/or megakaryocytic dysplasia achieve complete remission and longer survival after classical chemotherapy 3 + 7
- Right ventricular dysfunction after left ventricular assist device implantation
- Paraneoplastic thromboembolic syndrome as the first sign of a malignant disease
- Epidemiology of vascular disease